Melanie T Cushion

List of Publications by Year
in descending order

119 papers	3,520 citations	126907 33 h-index	175258 52 g-index
128 all docs	128 docs citations	128 times ranked	1914 citing authors

#	Article	IF	Citations
1	Pneumocystis carinii: Sequence from ribosomal RNA implies a close relationship with fungi. Experimental Parasitology, 1989, 68, 450-461.	1.2	207
2	Echinocandin Treatment of Pneumocystis Pneumonia in Rodent Models Depletes Cysts Leaving Trophic Burdens That Cannot Transmit the Infection. PLoS ONE, 2010, 5, e8524.	2.5	129
3	Pneumocystis and Trypanosoma cruzi: Nomenclature and Typifications. Journal of Eukaryotic Microbiology, 2006, 53, 2-11.	1.7	122
4	Reliability of calcein acetoxy methyl ester and ethidium homodimer or propidium iodide for viability assessment of microbes. Journal of Microbiological Methods, 1993, 17, 1-16.	1.6	119
5	Molecular Genetic Distinction ofPneumocystis cariniifrom Rats and Humans. Journal of Eukaryotic Microbiology, 1993, 40, 733-741.	1.7	112
6	Pneumocystis carinii: Growth variables and estimates in the A549 and WI-38 VA13 human cell lines. Experimental Parasitology, 1985, 60, 43-54.	1.2	100
7	Biofilm Formation by Pneumocystis spp. Eukaryotic Cell, 2009, 8, 197-206.	3.4	92
8	Phylogenomic Analyses Support the Monophyly of Taphrinomycotina, including Schizosaccharomyces Fission Yeasts. Molecular Biology and Evolution, 2009, 26, 27-34.	8.9	91
9	The ste3 Pheromone Receptor Gene of Pneumocystis carinii Is Surrounded by a Cluster of Signal Transduction Genes. Genetics, 2001, 157, 991-1002.	2.9	82
10	Phylogenetic identification of Pneumocystis murina sp. nov., a new species in laboratory mice. Microbiology (United Kingdom), 2004, 150, 1153-1165.	1.8	78
11	The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis. Antimicrobial Agents and Chemotherapy, 2016, 60, 7115-7127.	3.2	69
12	Gene Arrays at Pneumocystis carinii Telomeres. Genetics, 2005, 170, 1589-1600.	2.9	66
13	Pneumocystis carinii: Immunoblotting and immunofluorescent analyses of serum antibodies during experimental rat infection and recovery. Experimental Parasitology, 1987, 63, 319-328.	1.2	63
14	Molecular and phenotypic description ofPneumocystis wakefieldiaesp. nov., a new species in rats. Mycologia, 2004, 96, 429-438.	1.9	61
15	Pneumocystis: not just pneumonia. Current Opinion in Microbiology, 2005, 8, 393-398.	5.1	61
16	II. The genome ofPneumocystis carinii. FEMS Immunology and Medical Microbiology, 1998, 22, 15-26.	2.7	58
17	Transcriptome of Pneumocystis carinii during Fulminate Infection: Carbohydrate Metabolism and the Concept of a Compatible Parasite. PLoS ONE, 2007, 2, e423.	2.5	58
18	Pneumocystis carinii: Surface reactive carbohydrates detected by lectin probes. Experimental Parasitology, 1988, 67, 137-147.	1.2	56

#	Article	IF	Citations
19	Widespread Occurrence of Pneumocystis carinii in Commercial Rat Colonies Detected Using Targeted PCR and Oral Swabs. Journal of Clinical Microbiology, 2001, 39, 3437-3441.	3.9	56
20	In Vitro Studies of Pneumocystis carinii. Journal of Protozoology, 1989, 36, 45-52.	0.8	55
21	Early Acquisition of Pneumocystis carinii in Neonatal Rats as Evidenced by PCR and Oral Swabs. Eukaryotic Cell, 2002, 1, 414-419.	3.4	55
22	Analysis of Pneumocystis carinii Cyst Wall. II. Sugar Composition. Journal of Protozoology, 1990, 37, 436-441.	0.8	51
23	Inhibitors of Sterol Biosynthesis and Amphotericin B Reduce the Viability of Pneumocystis carinii f. sp. carinii. Antimicrobial Agents and Chemotherapy, 2000, 44, 1630-1638.	3.2	49
24	Stealth and Opportunism: Alternative Lifestyles of Species in the Fungal GenusPneumocystis. Annual Review of Microbiology, 2010, 64, 431-452.	7.3	49
25	Therapeutic Potential of Caspofungin Combined with Trimethoprim-Sulfamethoxazole for Pneumocystis Pneumonia: A Pilot Study in Mice. PLoS ONE, 2013, 8, e70619.	2.5	49
26	Pneumocystis: unraveling the cloak of obscurity. Trends in Microbiology, 2004, 12, 243-249.	7.7	47
27	Analysis of Pneumocystis carinii Cyst Wall I. Evidence for an Outer Surface Membrane. Journal of Protozoology, 1990, 37, 428-435.	0.8	45
28	Are Members of the Fungal Genus Pneumocystis (a) Commensals; (b) Opportunists; (c) Pathogens; or (d) All of the Above?. PLoS Pathogens, 2010, 6, e1001009.	4.7	45
29	Effects of Atovaquone and Diospyrin-Based Drugs on the Cellular ATP of Pneumocystis carinii f. sp. carinii. Antimicrobial Agents and Chemotherapy, 2000, 44, 713-719.	3.2	37
30	Novel bisbenzimidazoles with antileishmanial effectiveness. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2658-2661.	2.2	37
31	Parallel Solution-Phase Synthesis of Conformationally Restricted Congeners of Pentamidine and Evaluation of Their Antiplasmodial Activities. Journal of Medicinal Chemistry, 2004, 47, 2700-2705.	6.4	36
32	Sterol biosynthesis and sterol uptake in the fungal pathogen Pneumocystis carinii. FEMS Microbiology Letters, 2010, 311, 1-9.	1.8	36
33	V. Genetic heterogeneity of rat-derivedPneumocystis. FEMS Immunology and Medical Microbiology, 1998, 22, 51-58.	2.7	35
34	Imidazoquines as Antimalarial and Antipneumocystis Agents. Journal of Medicinal Chemistry, 2009, 52, 7800-7807.	6.4	35
35	Susceptibility of Pneumocystis to Echinocandins in Suspension and Biofilm Cultures. Antimicrobial Agents and Chemotherapy, 2011, 55, 4513-4518.	3.2	34
36	Cellular and Molecular Biology of Pneumocystis carinii. International Review of Cytology, 1991, 131, 59-107.	6.2	32

#	Article	IF	Citations
37	In Vitro Selection and In Vivo Efficacy of Piperazine- and Alkanediamide-Linked Bisbenzamidines against Pneumocystis Pneumonia in Mice. Antimicrobial Agents and Chemotherapy, 2006, 50, 2337-2343.	3.2	31
38	Draft Assembly and Annotation of the Pneumocystis carinii Genome. Journal of Eukaryotic Microbiology, 2006, 53, S89-S91.	1.7	31
39	Highly Active Anti- Pneumocystis carinii Compounds in a Library of Novel Piperazine-Linked Bisbenzamidines and Related Compounds. Antimicrobial Agents and Chemotherapy, 2004, 48, 4209-4216.	3.2	29
40	Anti-Pneumocystis carinii and antiplasmodial activities of primaquine-derived imidazolidin-4-ones. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 485-488.	2.2	29
41	Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and Pneumocystis Pneumonia. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	29
42	Latent Pneumocystis carinii Infection in Commercial Rat Colonies: Comparison of Inductive Immunosuppressants plus Histopathology, PCR, and Serology as Detection Methods. Journal of Clinical Microbiology, 1999, 37, 1441-1446.	3.9	28
43	Molecular and Phenotypic Description of Pneumocystis wakefieldiae sp. nov., a New Species in Rats. Mycologia, 2004, 96, 429.	1.9	27
44	Synthesis and SAR of alkanediamide-linked bisbenzamidines with anti-trypanosomal and anti-pneumocystis activity. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5884-5886.	2.2	25
45	PRIMACENES: novel non-cytotoxic primaquine-ferrocene conjugates with anti-Pneumocystis carinii activity. MedChemComm, 2010, 1, 199.	3.4	25
46	Characterization of a Distinct Host Response Profile to Pneumocystismurina Asci during Clearance of Pneumocystis Pneumonia. Infection and Immunity, 2013, 81, 984-995.	2.2	25
47	Diversity at the Locus Associated with Transcription of a Variable Surface Antigen of Pneumocystis carinii as an Index of Population Structure and Dynamics in Infected Rats. Infection and Immunity, 2003, 71, 47-60.	2.2	25
48	Molecular and phenotypic description of Pneumocystis wakefieldiae sp. nov., a new species in rats. Mycologia, 2004, 96, 429-38.	1.9	25
49	Fine analysis of the Pneumocystis carinii f. sp. carinii genome by two-dimensional pulsed-field gel electrophoresis. Gene, 2002, 293, 87-95.	2.2	24
50	Proposal for a Pneumocystis Genome Project. Journal of Eukaryotic Microbiology, 1997, 44, 7s-7s.	1.7	23
51	Novel bisbenzamidines as potential drug candidates for the treatment of Pneumocystis carinii pneumonia. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 4545-4548.	2.2	23
52	Has the Name Really Been Changed? It Has for Most Researchers. Clinical Infectious Diseases, 2005, 41, 1756-1758.	5.8	23
53	Preclinical Drug Discovery for New Anti-Pneumocystis Compounds. Current Medicinal Chemistry, 2009, 16, 2514-2530.	2.4	23
54	Comparative Genomics of Pneumocystis Species Suggests the Absence of Genes for myo- Inositol Synthesis and Reliance on Inositol Transport and Metabolism. MBio, 2014, 5, e01834.	4.1	23

#	Article	IF	Citations
55	Genomic insights into the host specific adaptation of the Pneumocystis genus. Communications Biology, 2021, 4, 305.	4.4	23
56	Cultivation of Pneumocystis carinii in Lung-Derived Cell Lines. Journal of Infectious Diseases, 1984, 149, 644-644.	4.0	21
57	Is sex necessary for the proliferation and transmission of Pneumocystis?. PLoS Pathogens, 2018, 14, e1007409.	4.7	21
58	Analysis of Current Antifungal Agents and Their Targets within the Pneumocystis carinii Genome. Current Drug Targets, 2012, 13, 1575-1585.	2.1	21
59	Sequence and structure of the linear mitochondrial genome of Pneumocystis carinii. Molecular Genetics and Genomics, 2010, 283, 63-72.	2.1	20
60	Gene Expression of Pneumocystis murina after Treatment with Anidulafungin Results in Strong Signals for Sexual Reproduction, Cell Wall Integrity, and Cell Cycle Arrest, Indicating a Requirement for Ascus Formation for Proliferation. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	20
61	Comparative Genomics of Pneumocystis carinii with Other Protists: Implications for Life Style1. Journal of Eukaryotic Microbiology, 2004, 51, 30-37.	1.7	19
62	Summary of Pneumocystis Research Presented at the 7th International Workshop on Opportunistic Protists. Journal of Eukaryotic Microbiology, 2001, 48, 101s-105s.	1.7	17
63	Assembly and Annotation of Pneumocystis jirovecii from the Human Lung Microbiome. MBio, 2013, 4, e00224.	4.1	17
64	The Persistent Challenge of Pneumocystis Growth Outside the Mammalian Lung: Past and Future Approaches. Frontiers in Microbiology, 2021, 12, 681474.	3.5	17
65	Evidence for multiple sterol methyl transferase pathways in Pneumocystis carinii. Lipids, 2002, 37, 1177-1186.	1.7	16
66	Competitive coexistence of two Pneumocystis species. Infection, Genetics and Evolution, 2006, 6, 177-186.	2.3	16
67	Stability of four genetic loci in Pneumocystis carinii sp. f. carinii. Journal of Eukaryotic Microbiology, 1996, 43, 49S-49S.	1.7	15
68	Constructing a Physical Map of the Pneumocystis Genome. Journal of Eukaryotic Microbiology, 1997, 44, 8s-8s.	1.7	15
69	Pneumocystis murina MSG gene family and the structure of the locus associated with its transcription. Fungal Genetics and Biology, 2007, 44, 905-919.	2.1	15
70	Analogs of pentamidine as potential anti-Pneumocystis chemotherapeutics. European Journal of Medicinal Chemistry, 2012, 48, 164-173.	5.5	15
71	Time between Inoculations and Karyotype Forms ofPneumocystis carinii f. sp. carinii Influence Outcome of Experimental Coinfections in Rats. Infection and Immunity, 2001, 69, 97-107.	2.2	14
72	A New Name (Pneumocystis jiroveci) for Pneumocystis from Humans (Response to Hughes). Emerging Infectious Diseases, 2003, 9, 277-279.	4.3	14

#	Article	IF	Citations
73	Standardization of an in vitro Drug Screening Assay by Use of Cryopreserved and Characterized Pneumocystis carinii Populations. Journal of Eukaryotic Microbiology, 2001, 48, 178s-179s.	1.7	13
74	Flow Cytometric Analyses of Lectin Binding to Pneumocystis carinii Surface Carbohydrates. Journal of Parasitology, 1992, 78, 271.	0.7	11
75	Rapid PCRâ€“Single-Strand Conformation Polymorphism Method To Differentiate and Estimate Relative Abundance of Pneumocystis carinii Special Forms Infecting Rats. Journal of Clinical Microbiology, 2001, 39, 4563-4565.	3.9	11
76	Diversity and Complexity of the Large Surface Protein Family in the Compacted Genomes of MultiplePneumocystisSpecies. MBio, 2020, 11, .	4.1	11
77	Immunobiology of <i>Pneumocystis carinii</i>. Pathology and Immunopathology Research, 1989, 8, 127-140.	0.8	10
78	The Pneumocystis Genome Project: Update and Issues. Journal of Eukaryotic Microbiology, 2001, 48, 182s-183s.	1.7	10
79	Validation of the name Pneumocystis wakefieldiae. Mycologia, 2005, 97, 268-268.	1.9	10
80	Mapping by Sequencing the Pneumocystis Genome Using the Ordering DNA Sequences V3 Tool. Genetics, 2003, 163, 1299-1313.	2.9	10
81	Ultrastructural Observations on Life Cycle Stages ofPneumocystis carinii. Journal of Protozoology, 1989, 36, 53s-54s.	0.8	9
82	Three New Karyotype Forms of Pneumocystis carinii f. sp. carinii Identified by Contoured Clamped Homogeneous Electrical Field (CHEF) Electrophoresis. Journal of Eukaryotic Microbiology, 2001, 48, 109s-110s.	1.7	9
83	Early Acquisition of Pneumocystis carinii in Neonatal Rats using Targeted PCR and Oral Swabs. Journal of Eukaryotic Microbiology, 2001, 48, 135s-136s.	1.7	9
84	Noninvasive Method for MonitoringPneumocystis cariniiPneumonia. Emerging Infectious Diseases, 2003, 9, 1613-1616.	4.3	9
85	Antitumor and Anti-Pneumocystis Carinii Activities of Novel Bisbenzamidines. Medicinal Chemistry Research, 2005, 14, 143-157.	2.4	9
86	Functional Characterization and Localization of Pneumocystis carinii Lanosterol Synthase. Eukaryotic Cell, 2010, 9, 107-115.	3.4	9
87	The Long-Acting Echinocandin, Rezafungin, Prevents Pneumocystis Pneumonia and Eliminates Pneumocystis from the Lungs in Prophylaxis and Murine Treatment Models. Journal of Fungi (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlo	3.4	9
88	A Survey of Birds in Denmark for the Presence of Pneumocystis carinii. Avian Diseases, 1994, 38, 1.	1.0	8
89	Large-Scale Characterization of Introns in the Pneumocystis carinii Genome. Journal of Eukaryotic Microbiology, 2006, 53, S151-S153.	1.7	8
90	Functional Characterization of Pneumocystis carinii Inositol Transporter 1. MBio, 2016, 7, .	4.1	8

#	Article	IF	Citations
91	Molecular Biology of Pneumocystis carinii. Annals of the New York Academy of Sciences, 1990, 616, 415-420.	3.8	7
92	Interactions between 2 Pneumocystis Populations within the Same Host. Journal of Eukaryotic Microbiology, 1997, 44, 9s-9s.	1.7	7
93	In Vitro and In Vivo Effects of Quinupristin-Dalfopristin against Pneumocystis carinii. Antimicrobial Agents and Chemotherapy, 2001, 45, 3234-3237.	3.2	7
94	Chloroquine Analogues as Leads against Pneumocystis Lung Pathogens. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	7
95	A quantitative systems pharmacology (QSP) model for Pneumocystis treatment in mice. BMC Systems Biology, 2018, 12, 77.	3.0	7
96	The 12th International Workshops on Opportunistic Protists (<scp>IWOP</scp>â€12). Journal of Eukaryotic Microbiology, 2013, 60, 298-308.	1.7	6
97	Serology and P carinii. Chest, 1987, 91, 935.	0.8	5
98	Validation of the name Pneumocystis wakefieldiae. Mycologia, 2005, 97, 268-268.	1.9	5
99	Microaerophilic Conditions Increase Viability and Affect Responses of Pneumocystis carinii to Drugs In Vitro. Journal of Eukaryotic Microbiology, 2006, 53, S117-S118.	1.7	5
100	Generation of Sequencing Libraries for the Pneumocystis Genome Project. Journal of Eukaryotic Microbiology, 2003, 50, 663-665.	1.7	4
101	The 14th International Workshops on Opportunistic Protists (<scp>IWOP</scp> 14). Journal of Eukaryotic Microbiology, 2018, 65, 934-939.	1.7	4
102	Kinetics of 2 Genetically Distinct Pneumocystis carinii Populations in Rat Colonies. Journal of Eukaryotic Microbiology, 1996, 43, 46S-46S.	1.7	3
103	Summary of the Pneumocystis Research Presented at the 6th International Workshop on Opportunistic Protists. Journal of Eukaryotic Microbiology, 1999, 46, 85s-152s.	1.7	3
104	The Promise of Lung Organoids for Growth and Investigation of Pneumocystis Species. Frontiers in Fungal Biology, 2021, 2, .	2.0	3
105	Rezafungin Prevention of Pneumocystis Pneumonia and Pneumocystis reactivation Using Different Doses and Durations of Prophylaxis in a Mouse Model. Blood, 2019, 134, 3266-3266.	1.4	3
106	Ash, L. R. & Orihel, T. C.1990.Atlas of Human Parasitology, 3rd ed.American Society of Clinical Pathologists, Chicago. ISBN 0-89189-292-3 (hardcover). 272 pp. Â£118.00.. Journal of Protozoology, 1992, 39, 741-742.	0.8	2
107	Expression Profiling of the Responses of Pneumocystis carinii to Drug Treatment Using DNA Macroarrays. Journal of Eukaryotic Microbiology, 2003, 50, 605-606.	1.7	2
108	The International Workshops on Opportunistic Protists. Journal of Eukaryotic Microbiology, 2006, 53, S1-S7.	1.7	2

#	Article	IF	Citations
109	Sequence of the Mitochondrial Genome of Pneumocystis carinii: Implications for Biological Function and Identification of Potential Drug Targets. Journal of Eukaryotic Microbiology, 2006, 53, S154-S155.	1.7	2
110	Pneumocystis DelanoÃ« & DelanoÃ« (1912). , 2011, , 709-717.		2
111	The State of Research for AIDS-Associated Opportunistic Infections and the Importance of Sustaining Smaller Research Communities. Eukaryotic Cell, 2012, 11, 90-97.	3.4	2
112	Pneumocystis 2006: Summary of the Research Presented at the Ninth International Workshop on Opportunistic Protists. Journal of Eukaryotic Microbiology, 2006, 53, S80-S84.	1.7	1
113	Advances in Genomics Research of Pneumocystis Species. , 2021, , 687-694.		1
114	II. The genome of Pneumocystis carinii. FEMS Immunology and Medical Microbiology, 1998, 22, 15-26.	2.7	1
115	Pneumocystis. , 0, , 2015-2029.		1
116	A Method for Isolation of RNA fromPneumocystis carinii. Journal of Protozoology, 1989, 36, 12s-14s.	0.8	0
117	Reply to Nevez et al., â€œThe Fascinating Echinocandin-Treated Mouse Model of Pneumocystis murina To Understand Pneumocystis jiroveciiâ€• Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	0
118	A Novel Encochleated Formulation Improves Atovaquone Activity in a Murine Model of Pneumocystis Pneumonia. Journal of Infectious Diseases, 2020, 224, 326-331.	4.0	0
119	Pathogenesis of Pneumocystis. , 0, , 347-361.		0